Compare BioNano Genomics Inc (BNGO) vs Celestica Inc (CLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Celestica Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Celestica Inc trades at $339.16 (market cap $39.16B). The key difference: Celestica Inc is far larger — about 2866.8× BioNano Genomics Inc's market cap, and Celestica Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | CLS | |
|---|---|---|
Market Cap | $13.66M | $39.16B |
Sector | Health | Technology |
52-Week High | $4.92 | $472.40 |
52-Week Low | $1.06 | $181.34 |
Enterprise Value | $16.26M | $39.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
CLS trades at $339.46, up 7.91% in 24 hours, with a bearish technical signal but strong fundamentals. Recent Q2 2026 EPS of $2.54 beat estimates, and revenue growth is driven by AI infrastructure demand. The company completed a $3 billion equity offering to fund expansion, though this may cause near-term dilution. Support levels are near $309, with resistance at $313.
Outlook is positive due to robust earnings beats and AI-driven growth, but risks include equity dilution and premium valuation. Analyst consensus is bullish with a $466.50 price target, indicating 37% upside. Investors should weigh growth potential against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Celestica Inc
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →
